Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 2

Status

Recruiting 8Active not recruiting 4Terminated 3Completed 3

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 2Other solid neoplasm 2Dermatologic 1

Conditions

Mesothelioma, Malignant 2Uveal Melanoma 1Neoplasms, Mesothelial 1Mesothelioma 1Adenoma 1

Interventions

Cyclophosphamide 166Docetaxel 154Bevacizumab 153Carboplatin 148Gemcitabine 146Cisplatin 146pembrolizumab 142Radiotherapy 135Paclitaxel 132Capecitabine 122Rituximab 115Oxaliplatin 104Fluorouracil 103Nivolumab 94Irinotecan 85Doxorubicin 85Pemetrexed 83Leucovorin 82Dexamethasone 82fludarabine 74fludarabine phosphate 72Bortezomib 69Etoposide 67Erlotinib Hydrochloride 66Cetuximab 65Methotrexate 58Trastuzumab 56Cytarabine 54Lenalidomide 50Everolimus 49

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Terminated × defactinib × Clear all
NCT04720417 2025-07-15

Defactinib and VS-6766 for the Treatment of Patients With Metastatic Uveal Melanoma

Thomas Jefferson University

Phase 2 Terminated
13 enrolled 13 charts
Dermatologic

Uveal Melanoma

NCT02004028 2024-02-20

Window of Opportunity Study of VS-6063 (Defactinib) in Surgical Resectable Malignant Pleural Mesothelioma Participants

Verastem, Inc.

Phase 2 Terminated
35 enrolled 15 charts
Other solid neoplasmThoracic

Mesothelioma, Malignant, Adenoma, Mesothelioma, Neoplasms, Mesothelial

NCT01870609 2017-01-30

COMMAND

Verastem, Inc.

Phase 2 Terminated
344 enrolled
Other solid neoplasmThoracic

Mesothelioma, Malignant

Data powered by HemOnc (CC BY 4.0) Colophon âš¡